Tranexamic acid: core drug for hemostasis and antifibrinolysis

Tranexamic Acid is a synthetic anti-fibrinolytic drug, mainly used to treat or prevent bleeding caused by hyperfibrinolysis, such as surgical bleeding, menorrhagia, etc. Its mechanism of action is to stabilize blood clots by inhibiting the activation of plasminogen and reducing the degradation of fibrin. This article will start from the pharmacological effects, clinical applications, product information and precautions, and systematically introduce the core content of tranexamic acid in five paragraphs.

Pharmacological effects and indications

Tranexamic acid inhibits fibrinolysis by competitively binding to the lysine binding site of plasminogen and blocking the binding of plasmin to fibrin. Its indications include:surgical bleeding(such as cardiac surgery, orthopedic surgery),postpartum hemorrhage,Menorrhagiaandhereditary angioedemaprevention. Studies have shown that tranexamic acid can reduce mortality in trauma patients (CRASH-2 clinical trial) and is included in the WHO essential medicines list.

Clinical application and dosage

Tranexamic acid is administered orally, intravenously, and topically. The usual dosage for adults is 1g each time, 2-3 times a day; in severe bleeding, 10-15mg/kg can be given intravenously. In the treatment of menorrhagia, it is taken orally 3-4 times a day for 3-5 days during the menstrual period. It should be noted that patients with renal insufficiency need to adjust the dose and avoid combined use with coagulation factor complexes to prevent the risk of thrombosis.

Product information and manufacturers

Summary and Notes

As a highly effective hemostatic drug, tranexamic acid needs to be strictly controlled for indications and should not be used in patients with a history of thrombosis or active vascular embolism. Common side effects include gastrointestinal reactions and rarely allergies or blurred vision. During clinical use, the risk of bleeding and thrombosis should be weighed and the principle of individualization should be followed. Its cost-effectiveness makes it an important emergency medicine worldwide.

Quote sources:
1. WHO Model List of Essential Medicines (2023 Edition)
2. CRASH-2 clinical trial (The Lancet 2010)
3. National Medical Products Administration drug database
4. Manufacturer’s official website: Pfizer, Daiichi Sankyo